What Astromech does
Astromech builds AI models that combine genomic, evolutionary, and functional data to forecast how living systems change over time. The company, spun out of Colossal Biosciences by Ben Lamm and George Church, says its platform learns from 3.8 billion years of biological history to anticipate drug resistance, pathogen evolution, and other biological risks. Dallas Innovates reports the company is in a research-and-development phase with operational research pipelines and plans forecasting pilots in health and biosecurity. The site currently offers only an early-access email signup rather than a live product.
Astromech is a research tool on Falcoscan. AI platform that predicts how biological systems will evolve. Falcoscan rates Astromech with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: hot. Astromech is founded in 2025, currently at Series_a stage. Pricing: Paid.